UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): January 24, 2011 (January 24, 2011)
Protalix BioTherapeutics, Inc.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
|
Florida
(State or other jurisdiction
of incorporation)
|
|
001-33357
(Commission File Number)
|
|
65-0643773
(IRS Employer
Identification No.) |
| |
|
|
|
2 Snunit Street
Science Park, POB 455
Carmiel, Israel
(Address of principal executive offices)
|
|
20100
(Zip Code) |
Registrant’s telephone number, including area code +972-4-988-9488
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
|
|
|
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
| o |
|
Pre-commencement communications pursuant to Ruled-2(b)
|
|
|
|
| o |
|
Pre-commencement communications pursuant to Rulee-4(c)
|
On January 24, 2011, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release
announcing that clinical data from the switchover trial of taliglucerase alfa in patients with
Gaucher disease and preclinical data on the oral enzyme glucocerebrosidase will be presented at the
7th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2011 being held February 16
through 18, 2011 in Las Vegas, Nevada. A copy of the press release is attached hereto as Exhibit
99.1.
|
|
|
| Item 9.01. |
|
Financial Statements and Exhibits |
| |
|
|
|
|
|
| |
99.1 |
|
|
Press release dated January 24, 2011. |
2